Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 18;16(14):2572.
doi: 10.3390/cancers16142572.

Clinical and Imaging Follow-Up for High-Risk Cutaneous Melanoma: Current Evidence and Guidelines

John T Vetto  1   2
Affiliations
Review

Clinical and Imaging Follow-Up for High-Risk Cutaneous Melanoma: Current Evidence and Guidelines

John T Vetto. Cancers (Basel). .

Abstract

The most recent (eighth) edition of the American Joint Committee on Cancer (AJCC) staging system divides invasive cutaneous melanoma into two broad groups: "low-risk" (stage IA-IIA) and "high-risk" (stage IIB-IV). While surveillance imaging for high-risk melanoma patients makes intuitive sense, supporting data are limited in that they are mostly respective and used varying methods, schedules, and endpoints. As a result, there is a lack of uniformity across different dermatologic and oncologic organizations regarding recommendations for follow-up, especially regarding imaging. That said, the bulk of retrospective and prospective data support imaging follow-up for high-risk patients. Currently, it seems that either positron emission tomography (PET) or whole-body computerized tomography (CT) are reasonable options for follow-up, with brain magnetic resonance imaging (MRI) preferred for the detection of brain metastases in patients who can undergo it. The current era of effective systemic therapies (ESTs), which can improve disease-free survival (DFS) and overall survival (OS) beyond lead-time bias, has emphasized the role of imaging in detecting various patterns of EST response and treatment relapse, as well as the importance of radiologic tumor burden.

Keywords: effective systemic therapies; high risk; imaging; melanoma; relapse; surveillance; tumor burden.

PubMed Disclaimer

Conflict of interest statement

The author has received honoraria from Castle Biosciences.

References

    1. Gershenwald J.E., Scolyer R.A., Hess K.R., Sondak V.K., Long G.V., Ross M.I., Lazar A.J., Faries M.B., Kirkwood J.M., McArthur G.A., et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J. Clin. 2017;67:472–492. doi: 10.3322/caac.21409. - DOI - PMC - PubMed
    1. Olsen C.M., Green A.C., Pandeya N., Whiteman D.C. Trends in melanoma incidence rates in eight susceptible populations through 2015. J. Investig. Dermatol. 2019;139:1392–1395. doi: 10.1016/j.jid.2018.12.006. - DOI - PubMed
    1. Surveillance, Epidemiology, and End Results Program: Cancer Stat Facts: Melanoma of the Skin. [(accessed on 21 May 2024)]; Available online: https://seer.cancer.gov/statfacts/html/melan.html.
    1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Melanoma: Cutaneous. Version 2.2024-April 3, 2024. [(accessed on 4 June 2024)]. Available online: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf.
    1. Trotter S.C., Sroa N., Winkelman Olenki T., Bechtel M. A global review of melanoma follow-up guidelines. J. Clin. Aesthet. Dermatol. 2013;6:18–26. - PMC - PubMed

LinkOut - more resources